Aveanna Healthcare (NASDAQ:AVAH) Major Shareholder Sells $25,875,000.00 in Stock

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) major shareholder J.H. Whitney Equity Partners V sold 2,250,000 shares of the business’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $11.50, for a total value of $25,875,000.00. Following the transaction, the insider directly owned 12,315,892 shares in the company, valued at $141,632,758. This trade represents a 15.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

J.H. Whitney Equity Partners V also recently made the following trade(s):

• On Thursday, August 20th, J.H. Whitney Equity Partners V sold 12,496,077 shares of Aveanna Healthcare stock. The stock was sold at an average price of $11.50, for a total value of $143,704,885.50.
• On Tuesday, June 30th, J.H. Whitney Equity Partners V sold 2,419,035 shares of Aveanna Healthcare stock. The shares were sold at an average price of $8.01, for a total transaction of $19,376,470.35.
• On Wednesday, June 24th, J.H. Whitney Equity Partners V sold 919,389 shares of Aveanna Healthcare stock. The stock was sold at an average price of $8.00, for a total transaction of $7,355,112.00.
• On Wednesday, June 3rd, J.H. Whitney Equity Partners V sold 5,842,240 shares of Aveanna Healthcare stock. The stock was sold at an average price of $6.24, for a total value of $36,455,577.60.

Aveanna Healthcare Stock Up 0.2%

Shares of NASDAQ:AVAH opened at $13.62 on Thursday. The firm has a market capitalization of $2.97 billion, a P/E ratio of 11.07, a P/E/G ratio of 0.85 and a beta of 1.90. The company has a debt-to-equity ratio of 4.47, a quick ratio of 1.16 and a current ratio of 1.16. The stock has a 50 day moving average price of $9.95 and a 200-day moving average price of $8.03. Aveanna Healthcare Holdings Inc. has a 52-week low of $5.93 and a 52-week high of $13.98.

Aveanna Healthcare (NASDAQ:AVAH) last issued its quarterly earnings results on Thursday, August 13th. The company reported $0.22 earnings per share for the quarter, topping the consensus estimate of $0.17 by $0.05. The company had revenue of $670.48 million for the quarter, compared to analysts’ expectations of $638.61 million. Aveanna Healthcare had a return on equity of 80.70% and a net margin of 10.56%. As a group, equities research analysts anticipate that Aveanna Healthcare Holdings Inc. will post 0.75 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently issued reports on AVAH shares. BMO Capital Markets increased their price target on shares of Aveanna Healthcare from $10.00 to $14.00 and gave the stock an “outperform” rating in a research note on Friday, August 14th. UBS Group boosted their price objective on shares of Aveanna Healthcare from $8.00 to $13.00 and gave the stock a “neutral” rating in a research note on Friday, August 14th. Barclays upped their price objective on shares of Aveanna Healthcare from $9.00 to $9.50 and gave the stock an “overweight” rating in a report on Thursday, July 9th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Aveanna Healthcare in a report on Thursday, July 2nd. Finally, Wall Street Zen cut Aveanna Healthcare from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 15th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Aveanna Healthcare has a consensus rating of “Moderate Buy” and a consensus price target of $12.89.

Institutional Trading of Aveanna Healthcare

Institutional investors have recently bought and sold shares of the company. AQR Capital Management LLC grew its position in Aveanna Healthcare by 21.2% during the 1st quarter. AQR Capital Management LLC now owns 26,280 shares of the company’s stock valued at $142,000 after purchasing an additional 4,602 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in Aveanna Healthcare by 8.3% in the first quarter. Goldman Sachs Group Inc. now owns 339,853 shares of the company’s stock worth $1,842,000 after buying an additional 25,974 shares during the last quarter. Jane Street Group LLC lifted its stake in shares of Aveanna Healthcare by 522.0% in the first quarter. Jane Street Group LLC now owns 75,081 shares of the company’s stock worth $407,000 after buying an additional 63,010 shares in the last quarter. Creative Planning lifted its stake in shares of Aveanna Healthcare by 15.1% in the second quarter. Creative Planning now owns 47,025 shares of the company’s stock worth $246,000 after buying an additional 6,171 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of Aveanna Healthcare by 65.0% during the second quarter. JPMorgan Chase & Co. now owns 158,265 shares of the company’s stock valued at $828,000 after buying an additional 62,348 shares during the last quarter. 87.96% of the stock is owned by hedge funds and other institutional investors.

Aveanna Healthcare Company Profile

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.